Clinical Trial: Tremelimumab as adjuvant therapy for non-small cell lung cancer without neoadjuvant treatment and with PD-L1 TPS ≥ 1: A single-arm, single-center phase I clinical study (China)

Posted On: 2026-09-10

China, Sept. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Tremelimumab as adjuvant therapy for non-small cell lung cancer without neoadjuvant treatment and with PD-L1 TPS ≥ 1: A single-arm, single-center phase I clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132065

Registration Time: 2026/09/09

Type: Interventional study

Primary Sponsor: The Affiliated Hospital of Qingdao University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342418

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Tremelimumab as adjuvant therapy for non-small cell lung cancer without neoadjuvant treatment and with PD-L1 TPS ≥ 1: A single-arm, single-center phase I clinical study (China)